After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
OVID belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Ovid Therapeutics Inc is $49.49M. A total of 0.72 million shares were traded on the day, compared to an average of 364.26K shares.
In the most recent transaction, ALEXANDER MARGARET A. bought 6,810 shares of OVID for 0.73 per share on Jan 27 ’25. After the transaction, the President and COO now owns 34,935 company shares. In a previous transaction on Mar 18 ’24, LEVIN JEREMY M bought 18,248 shares at 2.76 per share. OVID shares that CEO owns now total 3,616,715.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, OVID has a high of $4.10 and a low of $0.65.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. OVID’s latest balance sheet shows that the firm has $187.80M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $14.80M in liabilities at the time. Its Book Value Per Share was $1.07, while its Total Shareholder’s Equity was $179.75M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OVID is Buy with a score of 4.75.
